Coherus BioSciences Stock (NASDAQ: CHRS) stock price, news, charts, stock research, profile.
Open | $1.900 |
Close | $1.820 |
Volume / Avg. | 967.092K / 2.152M |
Day Range | 1.810 - 1.930 |
52 Wk Range | 1.430 - 5.630 |
Market Cap | $209.948M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 37 |
Short Interest | 22.17% |
Days to Cover | 10.58 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Coherus BioSciences (NASDAQ: CHRS) through any online brokerage.
Other companies in Coherus BioSciences’s space includes: Renovaro (NASDAQ:RENB), Innate Pharma (NASDAQ:IPHA), Abeona Therapeutics (NASDAQ:ABEO), Design Therapeutics (NASDAQ:DSGN) and INmune Bio (NASDAQ:INMB).
The latest price target for Coherus BioSciences (NASDAQ: CHRS) was reported by HC Wainwright & Co. on Friday, May 24, 2024. The analyst firm set a price target for 12.00 expecting CHRS to rise to within 12 months (a possible 555.74% upside). 24 analyst firms have reported ratings in the last year.
The stock price for Coherus BioSciences (NASDAQ: CHRS) is $1.83 last updated May 31, 2024 at 6:17 PM EDT.
There are no upcoming dividends for Coherus BioSciences.
Coherus BioSciences’s Q2 earnings are confirmed for Wednesday, July 31, 2024.
There is no upcoming split for Coherus BioSciences.
Coherus BioSciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.